5,3 mill. inhabitants - 900 Pharmacies
10,3 mill. inhabitants - 1.200 pharmacies
5.8 mill inhabitants - 580 pharmacies
5.5 mill inhabitants - 820 pharmacies
The market in Norway and the Nordic countries consists mainly of single products of Paracetamol and Ibuprofen
The combination product Maxigesic/Dolein represents an effective alternative first line of treatment for patients without having unnecessary doctor visits. This practice will reduce the pressure on the healthcare system. Thus, doctors need their patients to start a standard basic treatment before they visit the doctor’s office. If this first line of treatment does not work
– then you should see your doctor. An introduction of Maxigesicmay therefore be of great interest to both patient and doctor.
Norway: Total sold units Paracet
Norway: Total sold units Ibux
Denmark Total sold units Paracet
Denmark Toal sold units Ibux
Sweden Total sold units Paracet
Sweden Total sold units Ibux
A huge sale of the products in grocery stores, gasoline stations, kiosks and other shops
dominates the market within this sector. The total number of sales in these channels
are about 3 x the sale in Pharmacies.
This gives a large potential, but it will be of high importance that Maxigesic/Dolerin is authorized to be marketed as an OTC product. In Norway that would be in the same category as Viagra where the patients need to answer some questions in the pharmacy regarding their own health situation due to possible side effects.
The next phase in the market penetration is to get Maxigesic/Dolerin into the grocery stores, gasoline stations, kiosks and other shops. But we need to build trust and experiences in the pharmacies and with doctors .
Norway and Sweden have same structure concerning the pharmacies
with 3-4 big chains covering the marked.
Advanced my skills in end-to-end product development, from ideation to final design. Led the redesign of key interfaces, improving user satisfaction by 25%.
Currently leading design strategies for innovative products, managing a team of designers, and ensuring seamless user experiences.
Initially, we will recommend focusing on Sweden and Denmark. However, the dialog with the Norwegian authorities must start immediately. Due to important application dates in the Pharmacies chains in Sweden we should apply in October 2023. Denmark has another structure for entering the Pharmacy market.
Timeline Sweden/ Denmark
Total market for Norway, Sweden, Denmark in the OTC market for paracetamol and ibuprofen are in units 14.500.000. 30% of the market are combinations of paracetamol + ibuprofen or paracetamol + diclofenac. The most sold packages are paracetamol 500 mg x 20 tabl. and ibuprofen 400 mg x 20 tabl.
Since the market for OTC is growing, and we think that the paracetamol and ibuprofen combination will have great advantages, we would like to be positive in our prognosis – however there are factors like pricing, and that there are variable experiences with combination products. We also need to consider that after we have entered the market- our competitors will come up with generic products. We therefore need to downscale the numbers. Nevertheless we have high expectations:
2024- 3 % of the combination market
© Pharma Nordic AS – All rights reserved | Nettsiden er levert av Cateno AS